HL-60多药抗性细胞抗HT诱导凋亡机制的研究

用1mg·L-1三尖杉酯碱(Harringtoning,HT)处理人早幼粒急性白血病HL-60细胞2h,诱导细胞出现明显的凋亡(Apoptosis,Apo)形态学和生化特征,包括染色质凝集、Caspase-3(天冬氨酸特异的半胱氨酸蛋白水解酶-3)活化、DNA断裂等.来自HL-60的多药抗性细胞HR20和HT9抗HT诱导的凋亡,一般认为是P-糖蛋白(P-GP-170)对药物的外排作用引起细胞对凋亡的抗性.但用2mg·L-1 CsA(Cysclosporine A)逆转抗性细胞对药物的外排作用,1mg·L-1 HT作用48h仍不能诱导HR20和HT9细胞凋亡,说明HR20和HT9多药抗性细胞抗HT诱导凋亡的机制不仅仅在于细胞膜上的P-糖蛋白对药物的外排作用,可能还有凋亡相关因子或其他因素参与作用.Caspase-3是细胞凋亡通路中的一个中心环节,HR20和HT9抗HT诱导的Caspase-3活化,这可能是HR20和HT9不能凋亡的一个重要原因.     

The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel

We previously reported that treatment with P-glycoprotein (P-gp) substrates promotes in vitro invasion in multidrug-resistant (MDR) breast cancer cells. This effect is initiated by the P-gp pump function and mediated by interaction of P-gp with some unknown component(s). However, the underlying mechanism(s) remains poorly understood. Here we confirm a novel physical interaction between P-gp and cellular prion protein (PrP^c). Blocking P-gp activity or depletion of PrP^c inhibited paclitaxel (P-gp substrate)- induced invasion. Paclitaxel further facilitated the formation of P-gp/PrP^c clusters residing in caveolar domains and promoted the association of P-gp with caveolin-1. Both caveolin-1 and the integrity of caveolae were required for the drug-induced invasion. In addition, the P-gp/PrP^c complex also played an important role in anti-apoptotic activity of MCF7/Adr cells.These data provide new insights into the mode by which MDR breast cancers evade cytotoxic attacks from P-gp substrates and also suggest a role for P-gp/ PrP^c interaction in this process. Received 4 September 2008; received after revision 16 November 2008; accepted 18 November 2008     

横纹肌肉瘤多药耐药细胞系RD/VCR的建立

横纹肌肉瘤是一种高度恶性的软组织肿瘤，化疗是最主要的辅助治疗手段．然而，肿瘤细胞对药物产生多药耐药常常导致治疗失败．本实验以长春新碱为诱导剂，在体外成功建立了耐药细胞系DD／VCR，为进一步研究横纹肌肉瘤的耐药机理制作了模型．耐药前后细胞超微结构发生显变化，mdr1及mrp基因，P-糖蛋白及多药相关蛋白的表达与横纹肌肉瘤多药耐药的发生有关。     

P-glycoprotein and ‘lipid rafts’: some ambiguous mutual relationships (floating on them, building them or meeting them by chance?)

P-glycoprotein (P-gp) is an active membrane transporter responsible for cell detoxification against numerous amphiphilic compounds, leading to multidrug resistance in tumor cells. It displays entangled connections with its membrane environment since it recognizes its substrates within the cytosolic leaflet and it also translocates some endogenous lipids to the exoplasmic leaflet. Regarding its relationships with membrane microdomains, ‘lipid rafts’, a literature analysis concludes that (i) P-gp also exists in rafts and non-raft membrane domains, depending on the cell considered, the experimental conditions and the method used to test it; (ii) cholesterol has a positive influence on P-gp function, and this may be a direct effect of the free cholesterol present in membrane or an indirect effect mediated by the cholesterol-enriched microdomains; (iii) when present in rafts, P-gp interacts with protein partners regulating its activity; (iv) P-gp is a lipid translocase that handles the raft-constituting lipids with particular efficiency, and it also influences membrane trafficking in the cell. Received 18 November 2005; received after revision 23 December 2005; accepted 12 January 2006     

携SiRNA的聚乳酸羟基乙酸微球对Bel-7402/5-Fu细胞MDR1基因沉默作用的研究

目的 探讨携SiRNA的聚乳酸羟基乙酸(PLGA)微球通过沉默肝癌耐药细胞多药耐药基因(MDR1)基因,实现肝癌耐药的逆转.方法 合成针对MDR1的RNA干扰小片段(SiRNA),通过超声复乳法制备携药微球,转染肝癌耐药细胞Bel-7402/5 -Fu.运用Real-time PCR与Western blot方法,通过检测其mRNA及P糖蛋白表达水平,评价RNA干扰对MDR1表达的影响.MTT法检测RNA干扰逆转Bel-7402/5 Fu细胞对药性的效果,通过实验组细胞和对照组细胞之间的半数抑制剂量(IC50),计算RNA干扰组细胞的耐药逆转倍数.结果 在肝癌耐药细胞Bel-7402/5-Fu中,RNA干扰明显抑制了MDR1 mRNA和蛋白产物P糖蛋白的表达水平,且出现了P糖蛋白的持续低表达.MTT法显示,相同药物浓度下,实验组细胞生长明显受到抑制,表明其耐药性明显下降,其对药逆转倍数为11.56.结论 携SiRNA的PLGA微球能够有效减少肝癌耐药细胞Bel-7402/5-Fu的MDR1mRNA及P糖蛋白的表达水平,降低其耐药性.     

P-糖蛋白抑制剂维拉帕米对龙血素A、B、C在大鼠体内药物动力学影响

研究灌胃给予大鼠龙血竭后，P糖蛋白抑制剂维拉帕米对其有效成分龙血素A、B、C在大鼠血浆中的药物动力学影响.将SD大鼠随机分为对照组和抑制剂组并单次给药，对照组灌胃给予大鼠5 g/kg龙血竭，抑制剂组联合给予大鼠维拉帕米（1 mg/kg）和龙血竭（5 g/kg）.收集两组相同系列时间的血浆样本，采用HPLC-MS/MS的方法对龙血素A、B、C在大鼠血浆中的浓度测进行检测，求算两组血浆样本药物动力学参数.与对照组相比，抑制剂组大鼠龙血素A、B、C的血药浓度-时间曲线下面积分别增加109.4%，78.5%，22.8%，血药峰浓度分别增加69.6%，115.0%，42.1%，龙血素A、B的达峰时间均延长、龙血素C的达峰时间无变化，三者的生物半衰期（T_0.5）均变小，说明P糖蛋白抑制剂能够引起龙血素A、B、C在大鼠体内的血浆药物动力学参数变化，龙血素A、B、C均有可能为P糖蛋白的潜在底物.      

氢氯噻嗪在Caco-2细胞模型中的体外转运研究

采用体外培养的人小肠上皮细胞模型Caco-2考察浓度、时间、P-糖蛋白(P-glyprotein,P-gp)抑制剂维拉帕米(verapamil)以及pH对氢氯噻嗪(hydrochlorothiazide)跨膜转运的影响.氢氯噻嗪双向转运的Papp比值即Papp B→A/Papp A→B均大于1.5.在加入P-gp抑制剂维拉帕米后,氢氯噻嗪PappA→B极显著增大,Papp B→A降低,且Papp B→A/Papp A→B从2.87下降到0.67,加入前后有极显著差异(P0.01),且氢氯噻嗪的吸收转运随pH值的降低而显著增加.结果表明,氢氯噻嗪在Caco-2细胞模型中的吸收可能存在由载体介导的主动转运,同时它还受到P-糖蛋白的外排作用.     

The ABC transporter structure and mechanism: perspectives on recent research

ATP-binding cassette (ABC) transporters are multidomain integral membrane proteins that utilise the energy of ATP hydrolysis to translocate solutes across cellular membranes in all phyla. ABC transporters form one of the largest of all protein families and are central to many important biomedical phenomena, including resistance of cancers and pathogenic microbes to drugs. Elucidation of the structure and mechanism of ABC transporters is essential to the rational design of agents to control their function. While a wealth of high-resolution structures of ABC proteins have been produced in recent years, many fundamental questions regarding the proteins mechanism remain unanswered. In this review, we examine the recent structural data concerning ABC transporters and related proteins in the light of other experimental and theoretical data, and discuss these data in relation to current ideas concerning the transporters molecular mechanism.Received 29 August 2003; received after revision 19 November 2003; accepted 28 November 2003     

From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance

The ATP binding cassette (ABC) superfamily of membrane transporters is one of the largest protein classes known, and counts numerous proteins involved in the trafficking of biological molecules across cell membranes. The first known human ABC transporter was P-glycoprotein (P-gp), which confers multidrug resistance (MDR) to anticancer drugs. In recent years, we have obtained an increased understanding of the mechanism of action of P-gp as its ATPase activity, substrate specificity and pharmacokinetic interactions have been investigated. This review focuses on the functional characterization of P-gp, as well as other ABC transporters involved in MDR: the family of multidrug-resistance-associated proteins (MRP1-7), and the recently discovered ABC half-transporter MXR (also known as BCRP, ABCP and ABCG2). We describe recent progress in the analysis of protein structure-function relationships, and consider the conceptual problem of defining and identifying substrates and inhibitors of MDR. An in-depth discussion follows of how coupling of nucleotide hydrolysis to substrate transport takes place, and we propose a scheme for the mechanism of P-gp function. Finally, the clinical correlations, both for reversal of MDR in cancer and for drug delivery, are discussed.     

黄酮衍生物作为P糖蛋白抑制剂的构效关系研究

黄酮类化合物对P糖蛋白外泵作用的抑制效果越来越引起人们的关注.使用偏最小二乘法(PLS)和MolconnZ分子参数计算程序, 首次成功地构建了特异性地结合到P糖蛋白NBD2位点的黄酮类抑制剂的二维定量构效关系(2D-QSAR)模型.所得到的模型(尤其是模型D)表现出良好的可靠性和预测性,较好地关联了该类化合物结构特点和其对P糖蛋白抑制活性.这些模型对进一步合成和开发黄酮类P糖蛋白抑制剂有指导作用.